Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Open Access
- 8 April 2016
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 37 (6) , 1686-1696
Abstract
Acute myeloid leukemia (AML) is an aggressive clonal malignancy of hematopoietic progenitor cells with a poor clinical outcome. The resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating AML. Combining valproic acid (VPA) with other anti-leukemic agents has previously been noted as a useful and necessary strategy which can be used to specifically induce anticancer gene expression. In the present study, we demonstrated the synergistic antileukemic activities between VPA and cytarabine (Ara‑C) in a retrovirus-mediated murine model with MLL-AF9 leukemia, three leukemia cell lines (THP-1, K562 and HL-60) and seven primary human AML samples. Using RT-qPCR, we noted that the combination of VPA and Ara‑C significantly upregulated Bax expression and led to the arrest of leukemia cell proliferation, sub-G1 DNA accumulation and cell apoptosis, as demonstrated by flow cytometric analysis. Significantly, further experiments revealed that knockdown of Bax expression prevented VPA and Ara‑C‑induced cell apoptosis in THP-1 cells. The results of our present study demonstrated the synergistic antileukemic effect of combined VPA and Ara‑C treatment in AML, and thus we suggest that VPA be used an alternative treatment for AML.Keywords
This publication has 25 references indexed in Scilit:
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2015
- Acute myeloid leukemia: 2014 Update on risk‐stratification and managementAmerican Journal of Hematology, 2014
- Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patientsInternational Journal of Hematology, 2014
- Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsBlood, 2014
- The gene signature in CCAAT-enhancer-binding protein dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitorsHaematologica, 2013
- Outcomes of elderly de novo acute myeloid leukemia treated by a risk‐adapted approach based on age, comorbidity, and performance statusAmerican Journal of Hematology, 2013
- Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapseLeukemia & Lymphoma, 2012
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaLeukemia, 2010
- Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumorsCancer Treatment Reviews, 2008
- Increase in platelet count in older, poor‐risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all‐trans retinoic acidCancer, 2005